Impact of body mass index on overall survival in patients with metastatic breast cancer
Khalil Saleh, Matthieu Carton, Véronique Dièras, Pierre-Étienne Heudel, Étienne Brain, Véronique D’Hondt, Audrey Mailliez, Anne Patsouris, Marie‐Ange Mouret‐Reynier, Anthony Gonçalvès, Jean Marc Ferrero, Thierry Petit, George Emile, Lionel Uwer, Marc Debled, Florence Dalenc, Christelle Jouannaud, Sylvain Ladoire, Marianne Leheurteur, Paul Cottu, Lucie Véron, Alexia Savignoni, Coralie Courtinard, Mathieu Robain, Suzette Delaloge, Élise Deluche
Abstract
BACKGROUND: High Body mass index (BMI) is a risk factor for breast cancer among postmenopausal women and an adverse prognostic factor in early-stage. Little is known about its impact on clinical outcomes in patients with metastatic breast cancer (MBC). METHODS: The National ESME-MBC observational cohort includes all consecutive patients newly diagnosed with MBC between Jan 2008 and Dec 2016 in the 18 French comprehensive cancer centers. RESULTS: (range 12.1-66.5); 20% of women were obese and 5% underweight. Obesity was associated with more de novo MBC, while underweight patients had more aggressive cancer features. Median overall survival (OS) of the BMI cohort was 47.4 months (95% CI [46.2-48.5]) (median follow-up: 48.6 months). Underweight was independently associated with a worse OS (median OS 33 months; HR 1.14, 95%CI, 1.02-1.27) and first line progression-free survival (HR, 1.11; 95%CI, 1.01; 1.22), while overweight or obesity had no effect. CONCLUSION: Overweight and obesity are not associated with poorer outcomes in women with metastatic disease, while underweight appears as an independent adverse prognostic factor.